Spero therapeutics to present data at the 33rd european congress of clinical microbiology and infectious diseases

Cambridge, mass., april 14, 2023 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced two poster presentations at the 33r d european congress of clinical microbiology and infectious diseases (eccmid) being held april 15-18, 2023, in copenhagen, denmark.
SPRO Ratings Summary
SPRO Quant Ranking